.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Citi
Covington
McKinsey
Chinese Patent Office
Accenture
McKesson
Medtronic
AstraZeneca
QuintilesIMS

Generated: September 26, 2017

DrugPatentWatch Database Preview

Oritavancin diphosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for oritavancin diphosphate and what is the scope of oritavancin diphosphate freedom to operate?

Oritavancin diphosphate
is the generic ingredient in one branded drug marketed by The Medicines Co and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oritavancin diphosphate has one hundred and twenty-five patent family members in thirty-seven countries.

One supplier is listed for this compound.

Summary for Generic Name: oritavancin diphosphate

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list4
Clinical Trials: see list136
Patent Applications: see list7
Drug Prices:see low prices
DailyMed Link:oritavancin diphosphate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: oritavancin diphosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,952,466 Reductive alkylation of glycopeptide antibiotics► Subscribe
5,977,062 Glycopeptide antibiotic derivatives► Subscribe
5,843,889 Glycopeptide antibiotic derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: oritavancin diphosphate

Country Document Number Estimated Expiration
Australia5312196► Subscribe
Australia2015289602► Subscribe
Argentina010621► Subscribe
European Patent Office1016670► Subscribe
Portugal817797► Subscribe
Poland306976► Subscribe
Austria286910► Subscribe
Canada2272240► Subscribe
Finland117097► Subscribe
Norway992415► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ORITAVANCIN DIPHOSPHATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041-7Sweden► SubscribePRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323
0834Netherlands► SubscribePRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
/2016Austria► SubscribePRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
2016 00044Denmark► SubscribePRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
2016000075Germany► SubscribePRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
Julphar
Federal Trade Commission
Cerilliant
Healthtrust
Deloitte
US Department of Justice
Chinese Patent Office
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot